Optimal & the Court Hearing Date of August 8, 2025
OptimizeRx Corp has reported a surprising turnaround in Q2 2025, exceeding earnings and revenue estimates with a 55% increase in revenue and a 22% surge in stock price.
2 minutes to read
OptimizeRx Corp Reports Strong Q1 Performance, Raises Revenue Guidance Amid Subscription Model Success
OptimizeRx Corp reported strong Q1 2025 performance, with 11% revenue growth and improved EBITDA, leading to raised revenue guidance and a stock target increase to $14.
2 minutes to read